Enanta Pharmaceuticals (ENTA) Long-Term Investments (2012 - 2026)

Enanta Pharmaceuticals (ENTA) has 15 years of Long-Term Investments data on file, last reported at $63.2 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Investments changed N/A year-over-year to $63.2 million; the trailing twelve-month figure through Mar 2026 stood at $63.2 million (changed N/A YoY), and the FY2022 full-year result was $29.3 million, down 72.99% from the prior year.
• Long-Term Investments for Q1 2026 stood at $63.2 million, up from $56.1 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $63.2 million in Q1 2026 and bottomed at $5.9 million in Q2 2023.
• The 5-year median for Long-Term Investments is $39.4 million (2022), against an average of $35.6 million.
• The widest annual swing landed in 2023, when Long-Term Investments plunged 84.97%; it then surged 617.59% in 2024.
• A 5-year view of Long-Term Investments shows it stood at $26.9 million in 2022, then plunged by 78.01% to $5.9 million in 2023, then soared by 617.59% to $42.5 million in 2024, then surged by 31.86% to $56.1 million in 2025, then rose by 12.81% to $63.2 million in 2026.
• The last three Long-Term Investments figures came in at $63.2 million (Q1 2026), $56.1 million (Q4 2025), and $42.5 million (Q2 2024), per Business Quant data.

Peer Comparison